Abstract
Introduction
In the last twenty years, supervised injectable (SIH) and inhalable heroin prescribing has been developed, tested and in some cases implemented for limited groups of entrenched heroin users as a second-line treatment in a number of European countries and in Canada. This form of prescribing differs from that under the old 'British system' where the heroin prescription was taken away from the clinic setting and injected in an unsupervised context (Strang et al, 2012) . The new developments in supervised heroin prescribing have been based on over two decades of intensive research, mainly in form of randomised controlled trials (RCTs), to test its effectiveness on a range of outcome measures. These began with the Swiss studies from 1994 -1996 (Perneger et al, 1998 Rehm et al, 2001) , followed by the Dutch trials from (van den Brink et al, 2003 Blanken et al, 2010) , the German trial from -2005 (Haasen et al, 2007 , the Spanish trial from (March et al, 2006 , the British trial from 2005 -2008 (Strang et al, 2010 , the Canadian trial from 2005 -2008 , and more recently the Belgian trial from 2011-2013 (Demaret et al, 2015) . The evidence and expertise in this area have accumulated with each successive trial and demonstrated that heroin-assisted treatment (HAT) is more effective than oral methadone in reducing street heroin use, physical and mental health problems and criminal behaviour for methadone refractory heroin users (Strang et al, 2012) . Based on this international evidence, the Danish National Board of Health concluded that there was no need to launch their own trials of supervised injectable heroin (National Board of Health, 2008) . From March 2009, HAT was permitted in Denmark and the first clinic opened in Copenhagen in 2010. Denmark, Germany, the Netherlands and Switzerland have approved supervised heroin-assisted treatment as a second-line treatment and SIH clinics have been integrated into local treatment services.
Heroin-assisted treatment has been politically controversial in all of the countries that have conducted trials. It has been described by Khan et al (2014: 200) as 'one of the most controversial practices in clinical medicine despite its documented effectiveness'. This relates to the stigma associated with heroin as the perceived 'hardest drug' and the related stigmatisation and marginalisation of those who use it. It also is linked to paradox of treating those who are dependent on heroin with the very drug of dependency -heroin. Although HAT attracts much political attention, only a small proportion of heroin users receive such treatment. For example, in countries where HAT has been integrated into the treatment system, it accounts for between five and eight per cent of those enrolled in substitution treatment (Strang et al, 2012) . Several researchers have outlined the multiple challenges, barriers and restrictions involved in designing and conducting RCT research in this area, particularly in relation to negotiating the tensions between the demands of science and politics (Trujols and Iraurgi, 2009; Gartry et al, 2009; Small, Drucker et al, 2006; Wodak et al, 2002) . Against this challenging backdrop in each country, the scientists conducting the trials have relied on their epistemic authority and scientific integrity to counter the political challenges to the research and implementation of HAT. Science and scientists have played increasingly important roles in the acceptance and growth of HAT.
Drawing on Stone's concept of the 'knowledge network' (Stone, 2013 ) and Gieryn's theory of boundary-work (Gieryn, 1983) , this paper explores the development of the transnational network of scientists involved in the development of HAT across Europe and internationally, the ways in which the expertise and knowledge in this area has been constructed, exchanged, mobilized and transferred between key actors in the different countries and how the scientists have engaged in different forms of boundary-work to demarcate their expertise and knowledge from other forms. The paper begins by examining the concepts of knowledge networks and epistemic communities, followed by a description of the research design and methodology employed in the study. It then explores the ways in which expertise, ideology and interests were defined within the knowledge network around HAT, how this knowledge and expertise has been exchanged and transferred inside and outside the network and the ways in which the scientists have engaged in 'boundary-work' to demarcate 'science' from 'non-scientific activities'.
Knowledge networks, epistemic communities and boundary-work
The existing literature exploring the ways in which scientific evidence has been developed and invoked in the debates around heroin-assisted treatment has focused mainly on national case studies, for example in Denmark (Jepson, 2001; Houborg, 2010) and in the Netherlands (Dehue, 2002) , and the mapping of the network of HAT researchers through co-authorship analyses (Houborg and Munksgaard Anderson, 2015) . Research attention has not been directed towards the group of scientists from the various countries involved in the trials and their collective roles in the production, exchange and translation of this knowledge and expertise. Such qualitative analysis is important for understanding which forms of knowledge and expertise are defined as legitimate and credible and become reinforced over time through the mobilisation and transfer of scientific results and practices between scientists and other actors. This paper draws on concepts and theories from both the fields of global governance and the sociology of scientific knowledge. In order to explain the networking activities of the group of scientists involved in the development of heroin-assisted treatment transnationally, Stone's concept of the knowledge network will be employed (Stone, 2013 ). Gieryn's theory of boundary-work (Gieryn, 1983; 1999) will be applied to illuminate the social processes involved in the development and mapping of the science around HAT by the knowledge network.
Knowledge networks are not necessarily policy-focused, but they are engaged in advancing science around a specific topic or issue and concerned with "'codified' forms of knowledge produced by recognised intellectuals in the form of research and analysis" (Stone, 2003: 8) .
They produce, exchange and translate knowledge across national boundaries. Knowledge networks can take different shapes over time and many are not permanent entities. Inclusion in networks depends on 'official recognition of expert authority as well as more subtle and informal processes of validating scholarly and scientific credibility' (Stone, 2002: 2) . The expertise, scientific knowledge, professional experience and credentials of the actors in knowledge networks give them epistemic authority and credibility to inform policy and practice. The temporal aspect of the knowledge-policy interface is important as the influence of knowledge networks and knowledge actors may shift over time. As Stone (2012: 3) argues, influence rests in the aggregate contributions of wider networks of researchers who develop knowledge and evidence over time, rather than resting on individual contributions of lone scholars. This paper will explore how the knowledge network around HAT developed, the ways in which their knowledge and expertise was constructed and diffused between the different countries and how the aggregate contributions of the knowledge network built up over time and influenced the development of policy and practice.
The emergence of epistemic communities has become increasingly important within drugs policy-making at the European level (Elvins, 2003) . Epistemic communities are actor based, so attention is focused on the source of ideas and the development of supranational 'expert' networks in particular policy and practice domains. These communities aim to attain an authoritative voice in issue areas, generate 'multistakeholder dialogue' and build consensuswith resultant implications for policy and practice at national level. Haas (1992: 3) defines an epistemic community in the following way: "a network of professionals with recognized expertise and competence in a particular domain and an authoritative claim to policy-relevant knowledge within that domain or issue-area." Epistemic communities normally include professionals from a range of disciplines and backgrounds, but they must have shared normative and principled beliefs, causal beliefs, notions of validity and a common policy enterprise (Haas, 1992: 3).
As Demortain (2011) argues, Haas' conceptualisation is compelling because it offers three layers of explanation. First, the authority of science underpins the framework. The influence of scientists is dependent on them embodying scientific method, prestige and authority.
Where uncertainty surrounds policy problems (eg. drugs), epistemic communities provide knowledge to compensate for this uncertainty. Second, the notion of 'community' is important because it increases co-ordination between policy makers and scientists. Third, the involvement of professionals enhances the codification and authority of specialised expert knowledge. Scientists within epistemic communities act as 'experts' in the policy world.
Politicians and bureaucrats may turn to experts and their ideas at particular junctures.
However, the influence of experts only materialises when there is a connection between these two worlds (i.e. the scientific world and the policy world). In this perspective, the production of scientific knowledge is viewed as external or separate to politics and policy-making processes. Demortain (2011) scientists. This affects the content and type of research designed, commissioned, funded, conducted and published. These actors can play important roles as both gateways and gatekeepers to the types of knowledge produced. Government agencies negotiate the meaning and location of the boundaries and acceptability of science (Berridge, 2006) . As Stone (2013: 191) argues, the 'authorship of knowledge' extends beyond the scientists to a wide range of stakeholders who participate in and affect these processes. Knowledge is thus co-produced between scientists, policy makers and other actors.
Within post-positivist scholarship, the boundaries between science/experts and policy making are blurred. Backstrand (2004) argues that there is a constant re-evaluation of the status of expert knowledge and the boundaries between scientific and non-scientific knowledge, expert and lay knowledge, and global and local knowledge. Science, research and knowledge operate inside politics rather than outside it. This links to Gieryn's concept of 'boundarywork' and the ways in which the legitimacy, credibility and authority of scientific knowledge are maintained by establishing boundaries or borders between different types of professions/ disciplines/scientists, between different forms of knowledge and science and between the production of scientific knowledge and its consumption by non-scientists. These forms of demarcation and boundary-work are not only analytical matters, but linked to material opportunities, resources and professional authority (Gieryn, 1983 (Duke and Thom, 2014) . Drawing on these insights, this paper will explore the ways in which scientists in the area of heroinassisted treatment engaged in boundary-work and demarcated between different professions/disciplines, different forms of evidence and knowledge, and scientific and political domains.
Research Design and Methodology
The current study was based on a qualitative design that included documentary analyses, questionnaires and semi-structured interviews conducted between August 2013 and April 2015. In order to identify the 'knowledge network' in this area, a literature review, documentary analyses and short survey provided the foundation for the study. The Cochrane systematic review of heroin-assisted treatment (Ferri et al, 2011 ) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) review of evidence and practice (Strang et al, 2012) were useful points of departure to identify the key studies and their associated scientists. The literature review and documentary analyses were followed by a short survey questionnaire to the six EMCDDA National Focal Point representatives in the countries that had trials and/or had implemented heroin-assisted treatment. These Focal Points are responsible for collecting and collating data on their national drug situations to feed into the European monitoring system and thus have an overview of drugs research and expertise in their countries. The participants who completed the questionnaire were asked to identify which 'experts' they considered to be part of this particular knowledge network on HAT both in their own countries and internationally and who they recognised as influential within it. The short questionnaire included both closed and open-ended questions.
On the basis of the literature review, documentary analyses and results of the survey to EMCDDA focal points, key informants were identified for interview. A total of eleven semistructured interviews were conducted with a core group of scientists/researchers including eight trial scientists, one contributor to the Cochrane Drug and Alcohol Group, and two representatives from the EMCDDA. The interviews focused on the development of the network of scientists involved in HAT, how they interacted with each other over time, how they defined their expertise, and their roles in the production of knowledge and their influence on policy at international, European and national levels. Although semi-structured, the interviews also included open-ended discussion to allow participants to express their thoughts and experiences in their own way (Rubin and Rubin, 2011) . The interviews lasted around one hour and either took place face-to-face in the respondent's place of work, by telephone or by Skype. All of the interviews were recorded and transcribed.
The research was carried out using the prescribed ethical guidelines at the Drug and Alcohol Research Centre, Middlesex University and ethical approval was obtained from the Social Work Ethics Sub-committee.
1 Respondents were provided with an information sheet about the project outlining the background, purpose and format for the study and asked to sign a consent form. Participants were guaranteed confidentiality and anonymity. The network of scientists in this area of treatment is very small. In order to protect their identities, all identifiers such as details about the organisation, institution, department and country of origin have been removed in order to ensure that information is non-attributable.
At the end of the fieldwork, interview transcripts and notes were read systematically and all themes and categories emerging from the data were noted and coded on the transcripts. Some themes were derived from existing theory, literature and documents and had been covered systematically within the interviews while others were generated spontaneously and subsequently developed inductively during analysis.
Defining expertise, ideology and interests in heroin-assisted treatment (HAT)
The main scientists involved in HAT were identified through their publications, the review of evidence and current practices published by the EMCDDA in 2012 (Strang et al, 2012) and through questions in the interviews and questionnaires (See Table 1 ). Beginning with the Swiss trials in 1994, they acquired much knowledge and expertise through their development of this area of drug treatment and were viewed as the key experts due to their scientific knowledge. As one participant commented, they were seen to be the 'producers of the science'. Evans and Collins (2008) suggest that expertise is both social and performative in that experts are familiar with the formal aspects of knowledge along with the capacity to act and respond. They argue that expertise belongs to both individuals and communities and it is agreed, shared, transmitted and validated by a wider community. Within the group of principal investigators leading the trials, medical backgrounds and especially psychiatry dominated. The exception was the Canadian trial led by an epidemiologist and a psychologist. In most cases, the scientists conducting the trials were also clinicians. In line with their expertise, the approach followed a medical model with similarities to treating diseases like cancer. The goal was to provide an alternative treatment for those who were treatment refractory in opioid substitution treatment (Strang et al, 2012) .
In the interviews with the trial scientists, boundaries were drawn between the different professional, disciplinary and methodological backgrounds of the scientists involved in HAT research and others within the drugs field. In relation to the dominance of psychiatrists over other types of treatment researchers, one trials scientist commented that this was related to their professional authority and position, (Stone, 2013: 44) . The respondents also emphasised the importance of peer review in high impact medical journals to increase the credibility and acceptability of the findings. These 'products of expertise ' (McCann, 2008) in the form of publications, presentations, reports, and websites were important in the circulation of knowledge both inside and outside the knowledge network. Moreover, these products of expertise help to sustain, reinforce and reproduce the epistemic authority of the science over time (Gieryn, 1999) .
In some countries, the notion of expertise extended beyond medicine, psychiatry and experience in conducting RCTs. For example, in Canada, because the trial was not initiated by the government, the researchers had to gain the support of the government, funders and wider community. This process involved sensitive negotiations with the city of Vancouver, Health Canada, the local communities and the media (see Gartry et al, 2009) . Similarly, in order to move HAT from a scientific experiment to a routine treatment in some of the European countries, additional work and expertise was needed including registering injectable or inhalable heroin as a medication for opioid dependence with the European Medicines Agency (EMA), ensuring the inclusion of HAT on the list of provisions to be paid by health insurance in some countries, providing advice in order to revise the narcotics laws to provide the legal basis for HAT and in some cases arranging for the supply of prescription heroin for treatment purposes. These more tacit, practical forms of knowledge and negotiation were seen to be important by the scientists involved in the trials.
The motivation and interest on the part of the scientists to conduct work in this area was varied. Through their clinical work, some respondents had been working with heroin users who had not responded to conventional treatments (eg. methadone maintenance) and they were interested in exploring new ways of treating this small group. However, the authority, prestige and influence which comes from conducting research in such a controversial area may create incentives to draw the boundaries of science in certain ways (Gieryn, 1999 From the interviews, it was clear that the knowledge network was influenced by certain ideologies and perspectives in their work. In particular, they emphasised that were working with an unpopular and stigmatized group in a difficult area of public policy infused with moral judgements where the provision of heroin to 'drug addicts' was seen to be immoral by many sectors of society. One researcher referred to the group of trial scientists as 'pioneers' both in terms of advances in knowledge that they were making around this form of treatment, but also that they were prescribing the very substance of 'addiction' as treatment:
"They were pioneers because they were reverting the idea that treatment should take Although the respondents discussed the ideology of harm reduction in relation to their work, there was also a distancing away from any overt political advocacy. Where there is uncertainty and controversy surrounding a policy problem (i.e. drugs), the chance for scientific knowledge to gain ascendancy and authority can be undermined (Demortain, 2011) . Part of the pragmatic outlook of the scientists was the ways in which they emphasised their commitment and referral to the 'science' and their attempts to avoid becoming embroiled in moral and political arguments regarding drug use, criminalisation, and harm reduction. Some scientists who were interviewed stressed that it was important to stay neutral and as one trial scientist put it, 'to keep cool and stay on the science side of things'. In effect, a boundary was mapped between the scientific domain and the political arena which needed to be maintained in order for the science to be seen as 'objective' and command assent in the political debate. Given the potential political conflicts and the need to adhere to international drug control laws, the first Swiss and Dutch trials with HAT were also constructed in scientific terms rather than employing harm reduction arguments.
This placed the issue firmly in the hands of the medical researchers who were conducting the trials (Jepson, 2001 In policy areas of the greatest political controversy, some participants suggested that the science upon which decisions are based needed to be of the 'highest quality' in 'scientific'
terms. For them, the RCT design was seen to be the most robust in determining the efficacy of new treatments. It may be that this view was linked to the history of the original Swiss studies and the critique that emerged from the WHO external panel that these studies did not meet the criteria of randomised controlled trials, making it difficult to disentangle the specific effect of the heroin treatment and socio-psychological interventions (see Ali et al, 1998) .
Such criticisms are the result of applying 'traditional bio-medical criteria of scientific validity' (Jepson, 2001: 259) . As a result, the scientists chose to use what they perceived to be the most powerful research design (i.e. the so called 'gold standard' RCT) in subsequent trials, with the hope that the results could not be questioned by policy makers and politicians on methodological grounds.
Knowledge networks are perceived as sites of authority which emphasise a particular form of knowledge that is codified, technocratic and secular (Stone, 2013: 45) . Social practices in the networks provide their 'products' (i.e. ideas, publications and analyses), with scientific objectivity and technocratic neutrality. These scientific products create 'communication codes' that construct some types of knowledge as more persuasive and reliable. Participation in such networks is restricted by boundary drawing which excludes other forms of knowledge and expertise (e.g. experiential knowledge) which does not conform to techno-scientific criteria (Stone, 2003) . In the case of HAT, boundaries were drawn between the form of knowledge generated through the RCTs and the perspectives and knowledge of the patients involved which have rarely been prioritised or captured in the existing research (see Houborg, 2010; Boyd and NAOMI Patients Association, 2013) . This was acknowledged in the EMCDDA review (Strang et al, 2012) and recognised by all of the trial scientists. With the exception of a few qualitative studies that have explored the experiences of patients (e.g. Romo et al, 2009; Blanken et al, 2010) , the focus in this area of treatment has been almost exclusively on RCTs to determine its effectiveness in medical terms at the individual level. The evidence is limited by the artificial, clinical setting of the RCT and issues such as HAT's potential as a means to regulate heroin markets, the role of heroin in marginalised communities and the meaning of heroin within the wider economic and social contexts remain unexplored (Dehue, 2002; Wakeman, 2015) .
Developing a knowledge network: exchanging and transferring knowledge and expertise
The notion of the 'invisible college' (Crane, 1972) scientists were involved in the design of the Belgian study. These advisory groups provided the opportunity and an official mechanism to exchange ideas, experience and expertise in terms of planning and conducting the trials. It was important to the scientists that the different trials were comparable so that the evidence would build up over time. There was also an emphasis on ensuring that the trials complemented each other and that each trial added a new dimension or question to be answered (e.g. the German trial added different types of psychotherapy to injectable heroin, the UK trial added urine testing and included injectable methadone and the Canadian trials added injectable hydromorphone).
The network was not a formal or an official structure, but developed to support and help each other. They shared their knowledge, expertise and evidence of setting up and running the trials with each other in some cases to help to counteract the political resistance to the trials.
Because they were working in a controversial area with a highly stigmatised group, they experienced isolation in their own countries and needed each other's support and advice to deal with the resistance to their work: The scientists were attuned to the political nature of the research. Increasingly, over time they began to see their research in the aggregate, rather than as separate individual contributions.
They were conscious not to compete with each other, in contrast to other areas of science where intense competition between scientists exists (see for example, Collins, 1974) . The collaboration and cooperation between the scientists was also related to the fact that each team was representing a different country and they were not directly competing for the same research grants. As these comments illustrate, their collaboration and the complementary nature of the trials were important in showing a united front and ensuring the knowledge was communicated and transferred between themselves and to those in the policy arenas: The collaboration and 'comradeship' between the research teams was facilitated by face-toface visits to each other's countries and trial clinics. These meetings and visits were important in terms of the scientific and practical preparation for the trials. Similar to McCann's (2008) work on policy mobilities and expertise, the importance of physically seeing first-hand the clinics in operation helped to lay the ground work for acceptance, support and exchange amongst the research teams. If HAT could be achieved in one country, then this provided confidence and inspiration that it could be achieved in another country. The production of this knowledge was not completely separate from the social and political worlds of policy and practice. Members of the knowledge network were drawn into the policy process as 'reputational intermediaries' (Stone, 2003) or knowledge brokers to communicate and translate knowledge. This was evident when scientists in the knowledge network were invited to provide advice and present evidence relating to HAT to the Danish government. Similar to the work on policy translation, this highlights the power and the authority of the network to shape, transform and mediate the knowledge around HAT to new sites and contexts (Lendvai and Stubbs, 2007; Freeman, 2009 
Conclusion
The group of scientists involved in HAT formed a transnational knowledge network that worked across national boundaries to build an evolving evidence base and become a recognised site of authority. This was achieved through various modes of communication and interaction including face-to-face visits to the various countries and clinic sites, attending international conferences, as well as producing joint publications and reviews. Each study built on the previous one, generating layers of evidence, knowledge and expertise over time.
The science was 'mobile' in the sense that it impacted on the development of each successive study to ensure comparability and complementariness. The mobility and transfer of science and knowledge in this area was facilitated by a small group of scientists from predominantly medical backgrounds, working with the same research design (i.e. RCT) and protocols and answering the same scientific question (i.e. whether HAT could be an effective second-line treatment for heroin users). The controversial nature of the treatment and political resistance to it encouraged the scientists to collaborate and not compete with each other. This common enterprise resulted in a network that supported and shared their expertise with each other.
The HAT scientists engaged in different forms of boundary-work which included demarcating between different professions, between different forms of knowledge/science and between the production of scientific knowledge and its consumption by non-scientists.
They were unified by their discipline (mainly psychiatry), their clinician-academic roles, their methodological approach and the ideological perspective underpinning their work. They produced a specific form of science within the network, characterised by the medical model and the RCT design, and excluded other knowledges that do not conform to this particular techno-scientific criteria. Other types of science or research were rarely included in the network and in particular, qualitative work on the experiences of patients and their families and the effects of HAT on the wider society in terms of crime reduction and the impact on heroin markets were neglected. Clear boundaries were drawn which demarcated the particular form of evidence and expertise generated through the knowledge network and other forms of evidence and expertise. As recognised by the scientists involved in synthesising the existing evidence (Strang et al, 2012) , the voices, perspectives and expertise of the HAT patients and their families are missing from the existing research.
Knowledge networks both accrue and accredit authority (Stone, 2013) . The products of their expertise in the form of publications in high impact medical journals were viewed as vital in terms of increasing the credibility, authority and acceptability of their findings. However, science and scientists are only influential in policy terms if their scientific findings 'fit' with the wider political, economic and social contexts at particular junctures in time. Individually, many of the HAT scientists had influence in their own country on the development and implementation of HAT, on drug policy more generally and in other countries through advisory posts and their work as knowledge brokers. Furthermore, their aggregate contribution can be seen through the Danish example where HAT was implemented without a trial in Denmark because the existing evidence base from the other countries was seen to be both robust and applicable.
Although the scientists involved in the knowledge network were influenced by harm reduction ideologies, they did not crossover into overt political advocacy when the debate shifted from the scientific to the socio-political level. Acutely aware of the politics surrounding decisions regarding heroin-assisted treatment, the knowledge network appeared to see themselves in epistemic community terms in the sense that they communicated the science and knowledge around HAT as 'objective truths' which could be applied rationally in decision-making. For them, the science can be regarded as 'neutral' and a clear separation or boundary can be constructed between the production of scientific knowledge and political decision-making, thereby asserting their independence from the political arena based on their expert knowledge and professional authority.
The findings highlight the collective power of this group of scientists in producing a particular form of knowledge and expertise, how this has accrued over time, gained credibility and become legitimised, reinforced and reproduced by those who employ it in both scientific and political debates. The uniformity of the knowledge network in terms of their professional and disciplinary backgrounds, methodological expertise and ideological perspectives has meant that alternative forms of knowledge and perspectives have been neglected. This limits the nature and scope of the scientific evidence on which to base policy and practice decisions and impacts on the work of policy makers and practitioners as well as the experiences of those in treatment who are most affected by this research and policy development.
